Thirty-four abstracts from the chronic hepatitis C clinical development program of global research-based biopharmaceutical firm AbbVie were recently accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
The meeting will take place in San Francisco from Nov. 13-17.
AbbVie's presentations will focus on new data from Phase 3b studies of AbbVie's FDA-approved VIEKIRA PAK, which is indicated for use by adults with genotype 1 (GT1) chronic HCV infection, including studies of GT1 patients with chronic kidney disease and genotype 1b (GT1b) patients with compensated cirrhosis.
AbbVie representatives will also do presentations on the company's HCV pipeline medicines, ABT-493 and ABT-530.
"We are pleased to present new data from studies of the VIEKIRA PAK regimen in HCV patients, including those with chronic kidney disease and GT1b compensated cirrhosis," Michael Severino, executive vice president of research and development and chief scientific officer at AbbVie, said. "These data, as well as our findings from our investigational compounds, further demonstrate AbbVie's firm commitment to supporting the care of patients with chronic HCV infection."